No effect of the PPAR-γ agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo

Clinical Neuropathology

Volumn 28, Issue 6, 2009, Pages 430-439

  Kreutzer, Juergen ^a,b   Jeske, I ^a   Hofmann, B ^a   Blumcke, I ^a   Fahlbusch, R ^a   Buchfelder, M ^a   Buslei, R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Agonist; Cell culture; Cushing's disease; Medical therapy; Nelson's syndrome; PPAR ; Rosiglitazone

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; ROSIGLITAZONE;

ACTH SECRETING ADENOMA; ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROCORTISONE RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NELSON SYNDROME; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ADULT; FEMALE; HUMANS; HYDROCORTISONE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NELSON SYNDROME; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 70549112955     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.2379/NP300152     Document Type: Article

References (60)

1. Adams EF, Lei T et al. Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies. J Clin Endocrinol Metab. 1995; 80: 2077-2081.
2. Ambrosi B, Dall'Asta C et al. Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease. Eur J Endocrinol. 2004; 151: 173-178.
3. Assie G, Bahurel H et al. The Nelson's syndrome... revisited. Pituitary. 2004; 7: 209-215.
4. Atkinson AB, Kennedy A et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol. (Oxf) 2005; 63: 549-559.
5. Bochicchio D, Losa M et al. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab. 1995; 80: 3114-3120.
6. Boggan JE, Tyrrell JB et al. Transsphenoidal microsurgical management of Cushing's disease. Report of 100 cases. J Neurosurg. 1983; 59: 195-200.
7. Buslei R, Kreutzer J, Hofmann B, Schmidt V, Siebzehnrübl F, Hahnen E, Eyupoglu IY, Fahlbusch R, Blümcke I. Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas. Acta Neuropathol. 2006; 111: 264-271.
8. Chapuis Y, Chastanet S et al. Bilateral laparoscopic adrenalectomy for Cushing's disease. Br J Surg. 1997; 84: 1009.
9. Chapuis Y, Pitre J et al. Role and operative risk of bilateral adrenalectomy in hypercortisolism. World J Surg. 1996; 20: 775-779.
10. Coras R, Hölsken A, Seufert S, Hauke J, Eyüpoglu IY, Reichel M, Tränkle C, Siebzehnrübl FA, Buslei R, Blümcke I, Hahnen E. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth-factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther. 2007; 6: 1745-1754.
11. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932; 50: 137-195.
12. DeLellis RA, Loyd RV, Heitz PV, Eng C (eds). Pathology and Genetics of tumors of endocrine organs. Oxford: University Press; 2004.
13. Dorn LD, Burgess ES et al. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol. 1995; 43: 433-442.
14. Dubrovsky B. Adrenal steroids and the physiopathology of a subset of depressive disorders. Med Hypotheses. 1991; 36: 300-305.
15. Elstner E, Muller C et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998; 95: 8806-8811.
16. Estrada J, Boronat M et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997; 336: 172-177.
17. Etxabe J and Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40: 479-484.
18. Fahlbusch R, Buchfelder M et al. Transsphenoidal surgery for Cushing's disease. J R Soc Med. 1986; 79: 262-269.
19. Favia G, Boscaro M et al. Role of bilateral adrenalectomy in Cushing's disease. World J Surg. 1994; 18: 462-466.
20. Grabenbauer GG, Buchfelder M. Long-term results of pituitary irradiation in Cushing's disease. Strahlenther Onkol. 1997, 173: 533.
21. Grommes C, Landreth GE et al. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004; 5: 419-429.
22. Guilhaume B, Bertagna X et al. Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow-up studies. J Clin Endocrinol Metab. 1988; 66: 1056-1064.
23. Heaney AP, Fernando M et al. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002; 8: 1281-1287.
24. Heaney AP, Fernando M et al. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003; 111: 1381-1388.
25. Hofmann BM, Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res. 2006; 34: 158-184.
26. Kasperlik-Zaluska A, Hartwig W et al. Nelson's syndrome following bilateral total adrenalectomy. Endokrynol Pol. 1976; 27: 401-408.
27. Kasperlik-Zaluska A, Nielubowicz J et al. Nelson's syndrome: Incidence and prognosis. Clin Endocrinol (Oxf). 1983; 19: 693-698.
28. Kawai S, Ichikawa Y et al. 18 years mitotane therapy for intractable Cushing's disease. Lancet. 1999; 354: 951.
29. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res. 2003; 9: 1-9.
30. Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumors. Curr Opin Neurol. 2004; 17: 693-703.
31. Kubota T, Koshizuka K et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998; 58: 3344-3352.
32. Lamberts SW, van der Lely AJ et al. Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab. 1995; 80: 3111-3113.
33. Laws ER, Reitmeyer M et al. Cushing's disease resulting from pituitary corticotrophic microadenoma. Treatment results from transsphenoidal microsurgery and gamma knife radiosurgery. Neurochirurgie. 2002; 48: 294-299.
34. Lindholm J, Juul S et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86: 117-123.
35. Littley MD, Shalet SM et al. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf). 1990; 33: 445-455.
36. Liu DC, Zang CB et al. Anovel PPAR α/γ dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin. 2004; 25: 1312-1319.
37. Misra D, Kapur MM et al. Incidence of Nelson's syndrome and residual adrenocortical function in patients of Cushing's disease after bilateral adrenalectomy. J Assoc Physicians India. 1994; 42: 304-305.
38. Moore TJ, Dluhy RG et al. Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med. 1976; 85: 731-734.
39. Mullan KR, Leslie H et al. The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patiens with Nelson's syndrome. Clin Endocrinol (Oxf). 2006; 64: 519-522.
40. Munir A, Song F et al. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab. 2007; 92: 1758-1763.
41. Nagesser SK, van Seters AP et al. Long-term results of total adrenalectomy for Cushing's disease. World J Surg. 2000; 24: 108-113.
42. Nakane T, Kuwayama A et al. Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery. 1987; 21: 218-222.
43. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 2002; 5: 77-82.
44. Orth DN. Cushing's syndrome. N Engl J Med. 1995; 332: 791-803.
45. Pecori Giraldi F, Scaroni C et al. Effect of protracted treatment with rosiglitazone, a PPR-γ agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf). 2006; 64: 219-224.
46. Rees DA, Hanna FWF et al. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002; 56: 541-551.
47. Riederer B, Matus A. Differential expression of distinct microtubule-associated proteins during brain development. Proc Natl Acad Sci USA. 1985; 82: 6006-6009.
48. Schteingart DE, Tsao HS et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med. 1980; 92: 613-619.
49. Sheehan JM, Vance ML et al. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg. 2000; 93: 738-742.
50. Sonino N, Fava GA. Psychosomatic aspects of Cushing's disease. Psychother Psychosom.1998; 67: 140-146.
51. Sonino N, Zielezny M et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996; 81: 2647-2652.
52. Sood V, Colleran K et al. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther. 2000; 2: 429-440.
53. Stalla GK, Stalla J et al. Pharmacological modulation of CRH-stimulated ACTH secretion by ketoconazole. Horm Metab Res. 1987; 16 (Suppl.): 31-36.
54. Stalla GK, Stalla J et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology. 1988; 122: 618-623.
55. Suri D, Weiss RE. Effect of pioglitazone on adreno-corticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab. 2005; 90: 1340-1346.
56. Tindall GT, Herring CJ et al. Cushing's disease: results of transsphenoidal microsurgery with emphasis on surgical failures. J Neurosurg. 1990; 72: 363-369.
57. Wang M, Tafuri S. Modulation of PPAR-γ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem. 2003; 89: 38-47.
58. Werder Kv, Mueller OA. Cushing's Syndrome. Clinical endocrinology. A. Grossmann. Oxford: Blackwell; 1997.
59. Wilson CB, Tyrrell JB et al. Cushing's disease and Nelson's syndrome. Clin Neurosurg. 1980; 27: 19-30.
60. Zhu Y, Heaney FM. PPAR-ψ binds a putative PPRE in the POMC promoter. 86th Annual Meeting of the Endocrine Society. New Orleans: 2004.